Shionogi & Co Ltd (4507.T) Quote| Reuters.com
Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,253JPY
24 Jun 2016
Change (% chg)

¥-488 (-8.50%)
Prev Close
¥5,741
Open
¥5,778
Day's High
¥5,845
Day's Low
¥5,150
Volume
2,234,200
Avg. Vol
1,504,527
52-wk High
¥6,304
52-wk Low
¥3,985

4507.T

Chart for 4507.T

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, cold and sinus medicine, digestive medicine,... (more)

Overall

Beta: 1.11
Market Cap(Mil.): ¥1,844,518.00
Shares Outstanding(Mil.): 351.14
Dividend: 34.00
Yield (%): 1.18

Financials

  4507.T Industry Sector
P/E (TTM): 26.04 32.69 34.11
EPS (TTM): 201.73 -- --
ROI: 12.18 15.00 14.23
ROE: 13.55 16.08 15.46

BRIEF-Shionogi & Co Ltd adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen

* Says it adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen from 4,177.6 yen, effective from April 1

Jun 23 2016

Botswana gets GSK's modern HIV drug in largest ever Africa deal

LONDON An HIV drug first approved less than three years ago is being rolled out in Botswana as a core medicine for newly diagnosed patients, following the largest ever tender secured by GlaxoSmithKline's HIV business in Africa.

Jun 03 2016

GSK's modern HIV drug to be rolled out in Botswana

LONDON, June 3 An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare.

Jun 03 2016

BRIEF-Shionogi & Co submits new drug applications in Japan and U.S. for naldemedine

* Submits new drug applications in Japan and U.S. for Naldemedine for treatment of opioid-induced constipation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 30 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : MarketLine
$50.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.